leadf
logo-loader
viewPreveCeutical Medical Inc.

PreveCeutical Medical reports successful preliminary screening of key peptides from scorpion venom research program

'We have identified novel, lead peptide candidates that inhibit activity of a key protein implicated in driving the aggressive nature of certain brain cancers,' says Dr Harry Parekh, PreveCeutical’s chief research officer

scientists in a lab
The Vancouver company's research efforts include dual gene therapy for diabetes and obesity as well as Nature Identical peptides for the treatment of various ailments

PreveCeutical Medical Inc (CSE:PREV) (OTCMKTS:PRVCF) has announced positive results from the preliminary screening of key peptides from its scorpion venom-derived peptide research program that are set to pave the way for the creation of peptide therapies taking aim at brain cancer.

Via preliminary screening in a glioblastoma cell-based assay, PreveCeutical’s researchers succeeded in identifying four lead peptides from blue scorpion venom that inhibit the activity of a target protein that features in the progression of certain aggressive brain cancers.

READ: PreveCeutical explores partnerships with pharma and biotech companies for co-development of its Sol-Gel nasal delivery system

“We have identified novel, lead peptide candidates that inhibit activity of a key protein implicated in driving the aggressive nature of certain brain cancers,” said Dr Harry Parekh, PreveCeutical’s chief research officer. “From a practical perspective, these lead peptides are attractive as they are a fraction of the size and complexity of an earlier reported scorpion-derived peptide, Chlorotoxin.”

Dr Mak Jawadekar, president of PreveCeutical, was equally impressed.

“This is a key milestone for PreveCeutical, as this research program underway in Queensland, Australia has successfully identified four lead peptides from blue scorpion venom.” he said in a statement.

READ: PreveCeutical says C$16.25M Crushedit supply deal and Asterion Cannabis licensing deal among 2018 milestones

Headquartered in Vancouver, PreveCeutical is a health sciences company with five research and development programs. Its research efforts include dual gene therapy for diabetes and obesity, a soluble gel drug delivery program, Nature Identical peptides for the treatment of various ailments, non-addictive analgesic peptides as a replacement for morphine, fentanyl and oxycodone and a therapeutic product for treating athletes who suffer from concussions. PreveCeutical also sells CELLB9, an immune system booster containing minerals extracted from a peptide obtained from blue scorpion venom.

Preveceutical shares held steady at $0.035 in Monday’s morning trading session.

Contact Ellen Kelleher at ellen@proactiveinvestors.com

Quick facts: PreveCeutical Medical Inc.

Price: 0.045 CAD

CSE:PREV
Market: CSE
Market Cap: $22.14 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc. named herein, including the promotion by the Company of PreveCeutical Medical Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

PreveCeutical Medical announces completion on analgesic program is near

PreveCeutical Medical (CSE:PREV-OTCQB: PRVCF) CEO Stephen Van Deventer joined Steve Darling from Proactive Vancouver with news the company’s current stage of research for its disulfide linker technology will be completed soon. Van Deventer telling Proactive about the program and what the next...

on 23/7/20

2 min read